Neurological complications are frequently observed in association with HIV-1 infection. Up to a third of HIV-1 positive adults, and an even higher percentage of children, exhibit symptoms of the HIV-1 cognitive/motor complex-typified by cognitive and motor decline. 1 Widespread neuropathology is associated with this syndrome including reactive astrocytosis, white matter pallor and the occurrence of giant cells. 2 In addition, apoptotic death of populations of neurons and glia can also be observed, and this is presumed to be an important factor in the development of AIDSrelated cognitive and motor problems. 3 However, in spite of the fact that HIV-1 induced neuropathology has been frequently demonstrated, there is no consensus as to how these effects are produced. Recent research on the existence of chemokine receptors in the brain may help us to understand what is going on.
Over the last couple of years several extraordinary findings have completely revolutionized our understanding as to how the HIV-1 virus compromises the immune system, particularly the issue of how HIV-1 infects different types of immune cells (viral tropism). It is known that during the early phase of HIV-1 infection the cells that are targeted are mostly macrophages and dendritic cells. As the disease progresses viruses emerge that are able to infect T-lymphocytes-and this phase of the disease is associated with the rapid decline in immune function. In order to infect cells the HIV-1 virus first needs to bind to its target's surface by means of a receptor. Surprisingly, the relevant receptors turned out to be chemokine receptors. 4 Chemokines are a family of small proteins that carry chemotactic and other signals between different types of immune cells. 5 These effects are transduced through the activation of a family of G-protein coupled receptors (GPCRs). It was demonstrated that strains of HIV-1 that infected macrophage-like cells (M-tropic strains) utilized the CCR5 chemokine receptor in conjunction with the CD4 glycoprotein, whereas HIV-1 strains that targeted T lymphocytes (T-tropic strains) utilized the CXCR4 chemokine receptor together with CD4. Following binding to these receptors using the HIV-1 coat glycoprotein gp120, another HIV-1 protein, gp41, causes the viral envelope to fuse with the membrane of the target cell. Thus, the observation that chemokine receptors could act as cellular receptors for HIV-1 not only explained how the virus infected immune cells but also solved the problem of viral tropism. One consequence of these results is that it might be expected that chemokines would to be able to compete with HIV-1 for its binding sites on target cells. This prediction has been confirmed and it has been shown that raising the levels of agonists at CCR5 or CXCR4 receptors can inhibit HIV-1 infectivity in vitro. 6 Similar effects are also apparent in vivo. 7 Clearly, these results have major therapeutic implications.
So what about the brain? Why do neurons die and how are other features of HIV-1 induced neuropathology produced? HIV-1 probably enters the brain in association with infected macrophages and replicates in these cells as well as in resident microglia. However, it is quite clear that HIV-1 does not replicate in neurons. It has therefore been suggested that HIV-1 compromises neurons by an 'indirect' route. According to this model, HIV-1 infected microglia secrete neurotoxins or secrete factors which cause reactive astrocytes or macrophages to secrete neurotoxins. 8 Although there is a large list of molecules that could produce such effects, one prime candidate is thought to be the gp120 molecule which may be shed from infected microglia. Indeed, transgenic mice that overexpress gp120 develop neuropathology that is similar to that observed in human patients. 9 Furthermore, pure gp120 can produce neuronal apoptosis in cell culture models. In some models these effects are dependent on the presence of microglia/glia which is consistent with the indirect model, 10 although in other studies gp120 can apparently exert its effects directly on neurons. 11 Given what is known about the way in which HIV-1 binds to immune cells, what can we say about the effects of gp120 on neurons? Do these effects imply that, in addition to immune cells, neurons also express chemokine receptors and if so what is their significance?
Meucci et al, 12 have now examined the possiblity that neurons possess functional chemokine receptors, and they have also analyzed the way these may be involved in HIV-1 induced neuropathology. There is already a considerable literature on the consequences of activating neuronal GPCRs, and the stimulation of such receptors by neurotransmitters has important consequences for neuronal excitability and synaptic communication. 13 Activation of GPCRs leads to the intracellular release of G-protein ␤/␥ subunits which can then interact with neuronal K and Ca channels. In this way, the activation of inwardly rectifying K channels produces neuronal hyperpolarization and interaction with Ca channels is thought to be involved in presynaptic inhibition of transmitter release. In addition, activation of GPCRs can affect downstream biochemical pathways producing changes in intraneuronal Ca, effects on cAMP levels and modulation of MAPkinases. Meucci et al demonstrated that a variety of chemokines, capable of activating many of the known chemokine receptors, could produce Ca mobilization in pure neuronal cultures of hippocampal pyramidal neurons-suggesting that functional chemokine receptors were expressed by these cells. Interestingly, both M and T tropic gp120s were capable of producing the same effects indicating that they could also produce some receptor activation. Molecular biological experiments confirmed the presence of many types of chemokine receptors on these neurons including both CCR5 and CXCR4-the most prevalent types of receptors for M and T tropic gp120s. Therefore, these results indicate that chemokines and gp120s can bind to and activate neuronal chemokine receptors. Further analysis indicated that activation of these receptors produced many of the effects 'expected' of neuronal GPCRs, including presynaptic inhibition of glutamate release at excitatory synapses formed in the cultures, as well as inhibition of voltage-sensitive Ca channels.
Given the fact that chemokines can inhibit HIV-1 infection of immune cells, Meucci et al asked whether they could also inhibit gp120-induced neurotoxicity. The answer was clearly yes. However, this inhibitory effect was observed not only with chemokines that directly competed with gp120 for the same receptor, but it also occurred when other 'non competitive' chemokine receptors were activated. The authors argued therefore that direct competition between gp120 and chemokines was probably not the major mechanism by which neurotoxicity was prevented. This implied that these effects might be produced 'downstream' of receptor binding-at the level of intracellular signalling (see Image Section). Indeed, Meucci et al, demonstrated that chemokines could also prevent neuronal apoptosis induced by mechanisms that did not involve the use of gp120. Furthermore, they demonstrated that stimulation of neuronal chemokine receptors could increase the activation of MAPkinases that might mediate trophic effects of these molecules on neurons. In conclusion, it is clear that neurons do express an abundance of chemokine receptors. Activation of these receptors can produce rapid changes in neuronal excitability, which are typical of neuronal GPCRs, and they also can produce longer term signalling events that allow them to exert survival promoting effects on neurons. The authors speculated that interference with these signals by gp120 acting at the same receptors might be responsible for neuronal apoptosis. At any rate, the presence of neuronal chemokine receptors certainly suggests that HIV-1 induced neuropathology may be a direct result of gp120 action on neurons rather than, or in addition to, any indirect effects as previously suggested. Importantly, the anti-apoptopic effects of chemokines on neurons suggest that they may have therapeutic potential in a number of neurodegenerative disorders.
The presence of functional chemokine receptors on neurons is likely to be an extremely widespread phenomenon. Preliminary indications have demonstrated chemokine receptors in many parts of the brain.
14 It is obvious that these receptors are not expressed in anticipation of the arrival of HIV-1 and that they presumably normally subserve some role in control of neuronal activity and/or development. Indeed, it has been recently demonstrated that CXCR4 'knockout' mice exhibit gross deficits in cerebellar development. 15 One interesting possibility is that brain chemokine receptors may be involved in communication between the brain and the immune system and chemokine receptors in regions of the brain such as the area postrema would be ideally situated for undertaking such a role. It would clearly be easy to speculate on any number of interesting potential roles for neuronal chemokines and their receptors. What is certain is that the neurobiology of chemokines will be an extremely active area of investigation in coming years.
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